Mesothelioma is characterized by the inactivation of tumor suppressor genes, with frequent mutations in neurofibromin 2 (
NF2), BRCA1-associated protein 1 (
BAP1), and cyclin-dependent kinase inhibitor 2A (
CDKN2A). These mutations lead to disruptions in the Hippo signaling pathway
[...] Read more.
Mesothelioma is characterized by the inactivation of tumor suppressor genes, with frequent mutations in neurofibromin 2 (
NF2), BRCA1-associated protein 1 (
BAP1), and cyclin-dependent kinase inhibitor 2A (
CDKN2A). These mutations lead to disruptions in the Hippo signaling pathway and histone methylation, thereby promoting tumor growth.
NF2 mutations result in Merlin deficiency, leading to uncontrolled cell proliferation, whereas
BAP1 mutations impair chromatin remodeling and hinder DNA damage repair. Emerging molecular targets in mesothelioma include mesothelin (
MSLN), oxytocin receptor (
OXTR), protein arginine methyltransferase (
PRMT5), and carbohydrate sulfotransferase 4 (
CHST4).
MSLN-based therapies, such as antibody–drug conjugates and immunotoxins, have shown efficacy in clinical trials.
OXTR, upregulated in mesothelioma, is correlated with poor prognosis and represents a novel therapeutic target.
PRMT5 inhibition is being explored in tumors with
MTAP deletions, commonly co-occurring with
CDKN2A loss.
CHST4 expression is associated with improved prognosis, potentially influencing tumor immunity. Immune checkpoint inhibitors targeting PD-1/PD-L1 have shown promise in some cases; however, resistance mechanisms remain a challenge. Advances in multi-omics approaches have improved our understanding of mesothelioma pathogenesis. Future research will aim to identify novel therapeutic targets and personalized treatment strategies, particularly in the context of epigenetic therapy and combination immunotherapy.
Full article
